EGFR and neoplasm: Another phase II trial of cetuximab (initially 400 mg/m2, followed by weekly 250 mg/m2) was undertaken but in combination with carboplatin in 29 patients with recurrent platinum-sensitive OC or PPC (26 had EGFR positive tumours) resulted in three patients with CR (10.34%), six with PR (20.69%) and eight with SD (27.59%) [122].